vTv Therapeutics Inc.
NCM: VTVTLive Quote
📈 ZcoreAI Score
Our AI model analyzes vTv Therapeutics Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get VTVT Z-Score →About vTv Therapeutics Inc.
Healthcare
Biotechnology
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
📊 Fundamental Analysis
vTv Therapeutics Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -78.9%, which indicates that capital utilization is currently under pressure.
At a current price of $36.56, VTVT currently sits at the 75th percentile of its 52-week range (Range: $14.00 - $44.00).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$144.00M
Trailing P/E
--
Forward P/E
-9.82
Beta (5Y)
0.40
52W High
$44.00
52W Low
$14.00
Avg Volume
45K
Day High
Day Low